A federal judge in Virginia ruled Thursday that the Food and Drug Administration failed to adequately justify restrictions it placed on mifepristone, a drug used in medication abortions, finding the Biden-era rules unlawful. Montana abortion providers were among the plaintiffs in the 2023 lawsuit that brought the case, alongside providers in Kansas and Virginia.
The lawsuit argued that the FDA's restrictions on mifepristone — which govern how the drug can be prescribed, dispensed, and used — were excessive, unwarranted, and inconsistent with other legal standards applied to similar medications. The plaintiffs contended that the rules created unnecessary barriers for patients seeking medication abortion, particularly in rural states like Montana where geographic distance already limits access to in-person care.
The ruling does not immediately resolve all legal questions around mifepristone, which has been the subject of multiple federal court cases in recent years. The drug became the subject of intense legal scrutiny after the Supreme Court's 2022 Dobbs decision, which returned abortion regulation to individual states. Montana's constitution includes a right to privacy that state courts have interpreted as protecting abortion access, a protection that has been at the center of ongoing legislative and legal battles at the state level.
What the ruling means in practical terms for Montana patients and providers will depend on whether the FDA appeals and how lower courts apply the decision going forward. Montana providers involved in the suit have not yet issued public comment on the ruling's immediate effect on their practices.